Monday November 23 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Alliance for Regenerative Medicine

Thumbshot of's website
http://www.alliancerm.org

Alliance for Regenerative Medicine Names Executive Committee

Monday 5th of October 2009 14:19

-- Scott Wolchko: Chief Financial Officer, Fate Therapeutics

"I am delighted and honored to serve as the first chairman of the Alliance for Regenerative Medicine. The regenerative medicine community needs a strong and focused political voice and I am confident that this group of leading companies, research institutions, and non-profits that has come together will do just that," stated John Walker, CEO and president of iPierian and the newly elected Chair of the Alliance. "With the accelerating pace of development in regenerative medicine and new therapeutic advancements being introduced into the clinic at an ever increasing rate, it has never been more important that the companies and researchers involved in this field work together," added Dr. Anthony Atala, vice chair of the Alliance and the W.H. Boyce Professor, Director of the Institute for Regenerative Medicine and chair of the Department of Urology at Wake Forest University.

The charter members of the Alliance include: foundations and non-profits such as the Foundation for Regenerative Medicine, the Genetics Policy Institute, the Juvenile Diabetes Research Foundation, the Association of Clinical Research Organizations, and the New York Stem Cell Foundation; research institutions such as the Cleveland Clinic and the Wake Forest Institute for Regenerative Medicine; leading regenerative medicine life sciences companies Advanced BioHealing, Aldagen, ATTC The Global Bioresource Center, Geron, Fate Therapeutics, iPierian, Johnson & Johnson, Life Technologies, MaxCyte, Organovo, Pfizer Inc, Stem Cells Inc., Tengion, and Transgeneron Therapeutics; and investor organizations Kleiner, Perkins, Caufield and Byers, Proteus Ventures, Safeguard Scientific, and Toucan Capital.

"One of our first orders of business will be to establish a dialogue with the FDA and to work with Congress, and other parts of the Administration overseeing this field to help ensure safe and timely access to these new therapies," explained Dr. Leona Brenner-Gati, a newly elected officer of the Alliance and Vice President of Science and Technology at Johnson and Johnson.

In addition to its advocacy mission, the Alliance will serve as a source of information about regenerative medicine for policy makers, the media, and the general public. For more information about the Alliance, please visit the Alliance website at www.alliancerm.org or send an email to info@alliancerm.org. For specific questions please contact Michael Werner at mwerner@alliancerm.org (202.419.2515) or Morrie Ruffin at mruffin@alliancerm.org (301.328.1048).

SOURCE Alliance for Regenerative Medicine


Browse other news from this organisation: Alliance for Regenerative Medicine

Source PR Newswire

PR Newswire Logo
www.prnewswire.co.uk

Browse news from 2009

Download PDF PDF Version

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.